Results 61 to 70 of about 257,683 (336)
Arthritis Care &Research, Accepted Article.Objective Lupus low disease activity state (LLDAS) is a validated treatment target in systemic lupus erythematosus (SLE) but limited studies have explored the role of LLDAS in lupus nephritis (LN). This study aims to investigate the frequency and predictors of LLDAS attainment, and its benefit on LN relapse and renal function preservation in patients ...
Chak Kwan Cheung +6 more
wiley +1 more source
Azathioprine, cyclophosphamide and chlorambucil
Baillière's Clinical Rheumatology, 1990 Immunosuppressive agents serve a major role in the management of once-fatal conditions such as the systemic necrotizing vasculitides, but they are also being used in more common, chronic inflammatory disorders such as rheumatoid arthritis. The drugs are all capable of reducing cell division but they differ in their modes of action.
Luqmani, R, Palmer, R, Bacon, P
openaire +3 more sources
Hydroxychloroquine Associated with Lower Glomerular Filtration Rate Decline in Lupus Nephritis
Arthritis Care &Research, Accepted Article.Background Hydroxychloroquine (HCQ) protects kidney function in lupus nephritis (LN) by preventing flares, yet some cohort studies show no significant benefit in kidney function with HCQ. Clarifying these conflicting findings by showing early and long‐term benefits of HCQ on kidney function preservation is critical. Therefore, we analyzed data from our
Shivani Garg +9 more
wiley +1 more source
Outcome of pulse therapy in pemphigus: A 10-year study
Clinical Dermatology Review, 2018 Background: Pemphigus is a potentially fatal autoimmune blistering disease affecting the skin and mucosa. Pulse therapy has been tried in pemphigus in India and other countries with variable results.
Sirisha Varala +3 more
doaj +1 more source
Cancer Biology & Medicine, 2021 Objective: Promotion of the proliferative expansion of CD4+Foxp3+ regulatory T cells (Tregs) is one of the side effects that limits the use of bleomycin (BLM) in the treatment of tumors. In this study, we examined the hypothesis that cyclophosphamide (CY)
Ping Li +6 more
doaj +1 more source
Haematologica, 2017 Severe graft-versus-host disease is a major barrier for non-T-cell-depleted haploidentical stem cell transplantation. There is no consensus on the optimal graft-versus-host disease prophylaxis.
A. Ruggeri +17 more
semanticscholar +1 more source
Arthritis Care &Research, Accepted Article.Objective A leading cause of death among scleroderma (SSc) patients, interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool.
Cristina M Padilla +13 more
wiley +1 more source
Self‐Assembling Multi‐Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma
Advanced Healthcare Materials, EarlyView.A novel modular T‐cell engager platform, MATCH, is developed for personalized multiple myeloma therapy. MATCH uses complementary oligonucleotide‐linked Fab’ fragments to enable flexible targeting of MM antigens and controlled T‐cell activation. The system shows potent, antigen‐specific cytotoxicity in vitro and in vivo, highlighting its potential for ...
Shannuo Li +8 more
wiley +1 more source
Advanced Science, EarlyView.Sympathetic nerve innervation promotes the progression of Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma (EBV+ DLBCL) via β2‐adrenergic receptors. The discovery of enhanced nerve infiltration and β2AR expression reveals a novel mechanism and highlights the sympathetic–β2AR axis as a promising target for therapeutic intervention in EBV+ DLBCL.
Silan Huang +10 more
wiley +1 more source
Blood, 2016 Pomalidomide and low-dose dexamethasone (PomDex) is standard treatment of lenalidomide refractory myeloma patients who have received >2 prior therapies.
R. Baz +13 more
semanticscholar +1 more source